Skip to content
10-Q

Quarterly Report

Ibere Pharmaceuticals

0001410578-22-002405

← back to feed
Filed
Aug 12, 2022 12:00 AM ET
Period of report
Restated figures. One or more values in this filing restate previously reported amounts.

On SEC.gov

Financials in this filing

Metric Period Value
Operating Cash Flow Q2 2022 · Jun 30, 2022 −$524.21K
Operating Cash Flow Q2 2022 · Jun 30, 2021 −$623.23K
Short Term Debt Q2 2022 · Jun 30, 2022 $0
Cash And Equivalents Q2 2022 · Jun 30, 2022 $93.04K
Cash And Equivalents Q2 2022 · Dec 31, 2021 $458.39K
Stockholders Equity Q2 2022 · Jun 30, 2022 −$5.89M
Stockholders Equity Q2 2022 · Mar 31, 2022 −$7.28M
Stockholders Equity Q2 2022 · Dec 31, 2021 −$10.85M
Stockholders Equity restated Q2 2022 · Jun 30, 2021 −$12.92M
Stockholders Equity restated Q2 2022 · Mar 31, 2021 −$12.8M
Stockholders Equity Q2 2022 · Dec 31, 2020 $19.24K
Current Liabilities Q2 2022 · Jun 30, 2022 $398.01K
Current Liabilities Q2 2022 · Dec 31, 2021 $372.44K
Total Liabilities Q2 2022 · Jun 30, 2022 $6.17M
Total Liabilities Q2 2022 · Dec 31, 2021 $11.54M
Current Assets Q2 2022 · Jun 30, 2022 $275.81K
Current Assets Q2 2022 · Dec 31, 2021 $693.39K
Total Assets Q2 2022 · Jun 30, 2022 $138.38M
Total Assets Q2 2022 · Dec 31, 2021 $138.71M
Net Income Q2 2022 · Jun 30, 2022 $1.47M
Net Income Q2 2022 · Jun 30, 2022 $5.05M
Net Income Q2 2022 · Mar 31, 2022 $3.57M
Net Income Q2 2022 · Jun 30, 2021 −$112.27K
Net Income Q2 2022 · Jun 30, 2021 −$517.97K
Net Income Q2 2022 · Mar 31, 2021 −$405.7K
Operating Income Q2 2022 · Jun 30, 2022 −$140.53K
Operating Income Q2 2022 · Jun 30, 2022 −$443.14K
Operating Income Q2 2022 · Jun 30, 2021 −$233.76K
Operating Income Q2 2022 · Jun 30, 2021 −$328.24K